Takeda Pharmaceutical Company Limited
) recently announced the submission of a new drug application
(NDA) to the Ministry of Health, Labour and Welfare (MHLW) in
Japan for its drug Takepron (lansoprazole). The company is
seeking approval of a fixed-dose combination of Takepron and
low-dose aspirin for treating patients suffering from peptic
Patients taking low-dose aspirin to prevent recurrence of
cerebral infarction or myocardial infarction are on the rise with
Japan's aging population. We note that the administration of
low-dose aspirin may cause disorders such as gastric and duodenal
ulcer. Therefore, it becomes very important to prevent the onset
of ulcers in the said population group.
Takeda filed the NDA on the basis of a study of bioequivalence
between the fixed-dose combination therapy and two pills of
Takepron and low-dose aspirin.
We note that Takepron, a proton pump inhibitor, is already
approved for the prevention of recurrence of ulcers in patients
requiring administration of low-dose aspirin for a long period.
The patients have a history of gastric and duodenal ulcer.
We remind investors that a few days back Takeda submitted an
NDA for Adcetris (brentuximab vedotin) in Japan for the treatment
of adults suffering from relapsed or refractory CD30 positive
Hodgkin lymphoma (HL) and relapsed or refractory CD30 positive
anaplastic large cell lymphoma (ALCL).
Currently Takeda carries a Zacks Rank #4 (Sell).
Lannett Company, Inc.
) look better-positioned in the pharma space. They all carry a
Zacks Rank #1 (Strong Buy).
CYTOKINETCS INC (CYTK): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
TAKEDA PHARMACT (TKPYY): Get Free Report
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.